Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with
Effient(®) (prasugrel) compared with branded clopidogrel (
Plavix(®)) was more cost effective, and in most cases cost saving. These results were published in
Circulation on January 5, 2010.
In the pre-specified analysis of 6,705 patients, treatment with Effient compared with clopidogrel reduced total hospitalization costs over approximately 15 months, not including the cost of study drugs, by $530 per patient. This cost offset estimate includes bleeding-related costs that a sensitivity analysis showed were not a major driver of the overall cost difference between the two treatments.
The analysis also found that, including cost of the active study drugs as well as costs associated with the initial and subsequent hospitalizations, treatment with Effient compared with clopidogrel decreased cumulative medical costs by $221 per patient over the 14.7-month study. Study drug costs used in the analysis were the net wholesale price as of August 2009, which was $5.45 per day for Effient and $4.62 per day for clopidogrel.
"Results of the cost-effectiveness analysis showed that treatment with Effient was highly cost effective and an economically dominant option compared with Plavix," said David J. Cohen, M.D., M.Sc., director of cardiovascular research, Saint Luke's Mid America Heart Institute and professor of medicine, University of Missouri-Kansas City. "These favorable results were found in an analysis that considered only the first 30 days of treatment, as well an analysis that considered the time period starting from 31 days through the rest of the follow-up period. These analyses are important because the results provide the healthcare community, including formulary decision makers, with new data regarding the cost-effectiveness of Effient for patients with ACS undergoing PCI."